Delivery Order SPE2DB20D2104-SPE2DB25FMAYV

Award Date 10/21/24
Potential Completion Date 10/22/24
Potential Value $23K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of Gemtesa 75 mg tablets. The contract is valued at $5,111.05 and has an ultimate completion date of August 8, 2024. It is a firm-fixed-price contract for the delivery of this pharmaceutical product. AmerisourceBergen, a major pharmaceutical distributor, is the prime contractor for this award, which is not set-aside for any specific business type. The contract is...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,963.79, is for the delivery of Gemtesa 75 mg tablets. The contract has a firm fixed price pricing type and an ultimate completion date of November 1, 2024. The contract is a child contract and was awarded on October 31, 2024. There is no set-aside designation for this award....
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $86,501.38, is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product. The contract has a period of performance through February 12, 2025 and is a firm fixed-price delivery order. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,320.46, is for the delivery of Gemtesa 75 mg tablets and has a completion date of January 27, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999, which serves as a primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $23,340.41 firm fixed-price delivery order is for the supply of Gemtesa 75 mg tablets. The contract has a completion date of July 17, 2024 and was awarded on July 16, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,576.91, is for the delivery of Gemtesa 75 mg tablets over the period ending on April 7, 2025. This contract is not designated as a set-aside. It is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,139.87, is for the supply of GEMTESA 75 MG TABLET 30S, a pharmaceutical product. The contract has a period of performance through June 28, 2024 and is a Firm Fixed Price contract. This award is associated with a larger Indefinite Delivery Contract (IDC) that...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The $5,635.39 firm-fixed-price contract is for the delivery of the drug Gemtesa 75 mg tablet, with a completion date of August 2, 2024. This award is associated with AmerisourceBergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which covers a broad range of pharmaceutical products and medical supplies to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of GEMTESA 75 MG TABLET 90S. The contract is a firm fixed-price delivery order with a ceiling value of $2,013.21 and a period of performance through July 2, 2025. It is not set aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which provides a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA), a defense agency, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product. The contract has a firm fixed price of $1,987.43 and a period of performance through June 16, 2025. The contract is not set aside and was awarded on June 15, 2025. AmerisourceBergen Drug Corp holds a significant...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB25FMAYV
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $22,686.66, is for the supply of Gemtesa 75 mg tablets. The contract has a period of performance through October 2024 and is a firm fixed-price type. This appears to be a release against a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award does not have a set-aside designation, indicating open competition.

Generated 1/26/25, 12:06 AM